Local Recurrence of Giant Cell Tumor of Born After Intralesional Treatment with and without Adjuvant Therapy

May 2008
Journal of Bone & Joint Surgery, American Volume;May2008, Vol. 90-A Issue 5, p1060
Academic Journal
Background: The use of adjuvants after curettage has been well established for the treatment of giant cell tumor of bone. The purpose of this study was to analyze the rates of recurrence following different types of treatment as well as the influence of various factors of tumor presentation on those rates. Methods: The data regarding benign giant cell tumors of the appendicular skeleton from ten bone tumor centers were evaluated. Axial and malignant tumors were excluded. The recurrence rates associated with the different treatment modalities were analyzed, and hazard ratios for a recurrence were calculated for multiple factors of tumor presentation. Results: The study included 384 surgical procedures, involving 256 primary and 128 recurrent tumors. The mean duration of follow-up was 64.2 months. Wide excision was performed in seventy-eight cases (20.3%), and an intralesional procedure was done in 306 (79.7%). Of the intralesional procedures, 103 (33.7%) were performed without the use of adjuvants, 102 (33.3%) included filling with polymethylmethacrylate, seventy-four (24.2%) included polymethylme-thacrylate filling after phenolization, and twenty-seven (8.8%) included use of local toxins. The overall recurrence rate after the intralesional procedures was 49% when no adjuvants had been used, 22% when polymethylmethacrylate only had been used as an adjuvant, 27% when polymethylmethacrylate had been used after phenolization, and 15% when phenol or other local toxins had been used (without polymethylmethacrylate). The highest rate of recurrence (36%) after curettage with adjuvants was associated with extracompartmental tumors. Recurrent tumors were not at increased risk for another recurrence, even when they were extracompartmental. The recurrence rate following curettage of a primary tumor without the use of adjuvants (55%) was higher than that following the same treatment of a recurrent tumor (39%) (p = 0.033). Conclusions: Use of polymethylmethacrylate as an adjuvant significantly reduces the recurrence rate following intralesional treatment of benign giant cell tumors, and it appears to be the therapy of choice for primary as well as recurrent giant cell tumors of bone. The significantly better results following treatment of recurrent tumors without adjuvants compared with the results of the same treatment of primary tumors were probably related to increased surgical thoroughness brought about by the surgeon's awareness of dealing with a riskier tumor. Level of Evidence: Therapeutic Level III. See Instructions to Authors for a complete description of levels of evidence.


Related Articles

  • Giant Cell Tumor Of The Distal Ulna- A Rare Presentation Treated With Wide Resection And Stabilization Of The Ulnar Stump By The Extensor Carpi Ulnaris. Sharma, Rohit; Gupta, Sachin; Saini, Nitin; Kakkar, Vikas; Saini, Y.; Singh, Harpreet // Internet Journal of Orthopedic Surgery;2013, Vol. 21 Issue 1, p1 

    The location of a giant cell tumor (GCT) at the distal end of the ulna is very rare with a reported incidence from 0.45% to 3.2%. Various treatment options have been proposed. En-bloc resection of the distal part of the ulna maintaining extra-lesional margins with or without reconstruction or...

  • Giant cell tumour of bone: an analysis of 139 Indian patients. Saikia, Kabul; Bhuyan, Sanjeev; Borgohain, Munin; Saikia, Swapna; Bora, Anjan; Ahmed, Firoz // Journal of Orthopaedic Science;Sep2011, Vol. 16 Issue 5, p581 

    Background: Giant cell tumour of bone (GCT) is a benign but locally aggressive lesion. We analysed a series of GCTs of bone to determine whether there was any variation in the incidence and distribution in an Indian population compared to other populations reported in the literature, as well as...

  • Giant Cell Tumor of Bone. Cavanna, Luigi; BIASINI, CLAUDIA; MONFREDO, MICHELA; MANISCALCO, PIETRO; MORI, MONICA // Oncologist;Nov2014, Vol. 19 Issue 11, p1 

    A positron emission tomography/computed tomography image of a giant cell tumor of the right fibula is presented and discussed.

  • Giant cell tumor of the metacarpal bones. Saikia, Kabul C.; Bhuyan, Sanjeev K.; Ahmed, Firoz; Chanda, Debashish // Indian Journal of Orthopaedics;Sep/Oct2011, Vol. 45 Issue 5, p475 

    Giant cell tumor (GCT) of hand bones is rare. We present two cases of GCT of metacarpal bone. One case was treated successfully with ray amputation. The second patient underwent wide resection and tricortical iliac crest bone grafting. Till the last follow-up (at 26 and 70 months respectively)...

  • Giant cell tumor of the fifth lumbar vertebra with a three-year follow-up: case report and review of the literature. Athanassacopoulos, Michael; Triantafyllopoulos, Georgios; Pneumaticos, Spyridon // European Journal of Orthopaedic Surgery & Traumatology;Nov2012 Supplement, Vol. 22, p15 

    We report the case of a patient with giant cell tumor of the L5 vertebra. A 35-year-old female patient with giant cell tumor of the L5 vertebra was subjected to a combined treatment. Three years after treatment, there is no recurrence of the disease and no increase in the residual tumor's size....

  • Array-based comparative genomic hybridization for genomic-wide screening of DNA copy number alterations in aggressive bone tumors. Kanamori, Masahiko; Sano, Akimi; Yasuda, Taketoshi; Hori, Takeshi; Suzuki, Kayo // Journal of Experimental & Clinical Cancer Research (17569966);2012, Vol. 31 Issue 1, p1 

    Background: The genetic pathways of aggressive changes of bone tumors are still poorly understood. It is very important to analyze DNA copy number alterations (DCNAs), to identify the molecular events in the step of progression to the aggressive change of bone tissue. Methods: Genome-wide...

  • Osteoclastoma. Rai, K. Manjunath; Venkateswarlu, S. // Indian Journal of Radiology & Imaging;Feb2008, Vol. 18 Issue 1, p4 

    The article presents information on osteoclastoma, which forms around 20% of all bone tumours. Accordingly, the giant cell tumour would have occurred for sometime before the patient is assigned to roentgenologic examination. It says that some cases of osteoclastoma are treated only by radiation,...

  • Giant Cell Tumor of Bone in a Child with Goltz Syndrome. LEI SHAO; MARDIS, NEIL; NOPPER, AMY; JARKA, DALE; SINGH, VIVEKANAND // Pediatric & Developmental Pathology;Jul/Aug2013, Vol. 16 Issue 4, p308 

    Giant cell tumor of bone is a neoplasm that is rarely seen in children. Goltz syndrome is a disorder that affects multiple ectodermal and mesodermal tissues and has occasionally been associated with giant cell tumors of bone. Our case of giant cell tumor in a 5-year-old girl with Goltz syndrome...

  • The Surgical Treatment and Outcome of Pathological Fracture in Patients with Giant Cell Tumor of Bone. Torigoe, Tomoaki; Terakado, Atsuhiko; Suehara, Yoshiyuki; Okubo, Taketo; Takagi, Tatsuya; Kaneko, Kazuo; Yazawa, Yasuo // Surgical Science;Jul2011, Vol. 2 Issue 5, p228 

    Between 1992 and 2008, we treated 35 patients with giant cell tumor (GCT) of bone, seven of the 35 presented with a pathological fracture. The fractures were located in the femur in five, and in the humerus and radius in one patient each. The surgical treatments were curettage in six cases and...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics